Tag: HER2-negative GEJ treatment

Home / HER2-negative GEJ treatment

Categories

Pembrolizumab with chemotherapy is approved by the USFDA for HER2-negative gastric or gastroesophageal junction adenocarcinoma

The Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with fluoropyrimidine- and platinum-containing chemotherapy on November 16, 2023. This approval is for the ini...
her2-negative-gej-treatment

Scan the code